Tolperisone

When ATH:
M03BX04

Characteristic.

Muscle relaxants centrally acting.

Pharmacological action.
Miorelaksiruyuschee.

Application.

Treatment pathologically increased muscle tone and spasms striated muscles due to organic diseases of the CNS (incl. the defeat of the pyramidal tract, multiple sclerosis, stroke, myelopathy, encephalomyelitis), as well as the accompanying diseases of the musculoskeletal system (incl. spondylosis, spondylarthritis, cervical and lumbar syndromes, arthrosis of large joints); medical rehabilitation after orthopedic and trauma operations; in a combination therapy of obliterating vascular diseases (atherosclerosis, diabetic angiopathy, thromboangiitis obliterans, Raynaud's syndrome), Diseases, occurring disorders based on vascular innervation (acrocyanosis, intermittent angioneurotic disbaziya). In Pediatrics - Little's Disease (children's cerebral palsy) and other encephalopathies, accompanied by muscle dystonia.

Contraindications.

Hypersensitivity, myasthenia, Children up to age 1 year.

Pregnancy and breast-feeding.

During pregnancy (especially in the I trimester) and during breastfeeding can be used only in case of, if the expected benefit to the mother outweighs the potential risk to the fetus.

Side effects.

From the nervous system and sensory organs: muscular weakness, headache, drowsiness.

From the digestive tract: nausea, vomiting, abdominal discomfort (usually take place at a reduced dose).

Allergic reactions: anaphylactic shock, bronchospasm, hives, эritema, itching.

Other: decrease in blood pressure.

Cooperation.

The effect of tolperisone increase funds for anesthesia, Peripheral muscle relaxants, psychotropic drugs, klonidin. It may be used in combination with sedatives, hypnotics and drugs, containing alcohol. No impact on the effect of alcohol on the central nervous system. Tolperisone enhances the action of acid niflumic (while the application may require dose reduction niflumic acid).

Overdose.

Data on overdose were reported. It has a wide therapeutic range, the literature describes the use of drugs in children oral dose 600 mg without causing serious toxic symptoms. If ingestion of 300-600 mg per day in children and in some cases observed irritability.

In the study of acute oral toxicity in animal studies high doses caused ataxia, tonic and clonic seizures, shortness of breath and respiratory paralysis.

Possible symptoms: respiratory depression (by paresis diaphragm and direct braking respiratory center) and cardiac activity, hypotension.

Treatment: gastric lavage, symptomatic and supportive therapy. No specific antidote.

Dosing and Administration.

Inside, adult - usually starting with 50 mg 2-3 times a day, gradually increasing the dose to 150 mg 2-3 times a day. Children from 1 Year to 6 years - 5 mg / kg / day., children 7-14 years - 2-4 mg / kg / day. (in 3 receiving during the day).

Cooperation